Acute Lymphoblastic Crisis in a Patient with Chronic Lymphatic Leukemia

1975 ◽  
Vol 54 (5) ◽  
pp. 306-311 ◽  
Author(s):  
A. Klajman ◽  
A. Yaretzky ◽  
J. Manor ◽  
Z. Steiner
Keyword(s):  
Chronic Lymphatic Leukemia ◽  
Lymphatic Leukemia

scholarly journals A real-time PCR assay for the quantification of residual malignant cells in B cell chronic lymphatic leukemia

Leukemia ◽  
2000 ◽  
Vol 14 (4) ◽  
pp. 754-766 ◽  
Author(s):  
T Pfitzner ◽  
A Engert ◽  
H Wittor ◽  
T Schinköthe ◽  
F Oberhäuser ◽  
...  
Keyword(s):  
B Cell ◽  
Real Time ◽  
Real Time Pcr ◽  
Malignant Cells ◽  
Chronic Lymphatic Leukemia ◽  
Pcr Assay ◽  
Lymphatic Leukemia

Use of immunocorrectors in patients with chronic lymph leukemia

1986 ◽  
Vol 67 (2) ◽  
pp. 99-101
Author(s):  
V. Ya. Shustov ◽  
N. A. Afanasyeva ◽  
P. P. Kuznetsov ◽  
A. K. Myshkina
Keyword(s):  
Immune System ◽  
Outpatient Treatment ◽  
Infectious Complications ◽  
Chronic Lymphatic Leukemia ◽  
Cytostatic Drugs ◽  
Ability To Work ◽  
Lymphatic Leukemia ◽  
Long Time ◽  
Negative Effect

Chronic lymphatic leukemia is second only to acute leukemia in the frequency of infectious complications. In most cases, severe infectious complications are the cause of death in these patients. Modern chemotherapy makes it possible to preserve the ability to work and the life expectancy of patients for a long time. However, the negative effect of cytostatic drugs on the already altered immune system leads to an even greater suppression of immunity and an increase in the number of infectious complications. The search for new ways to combat infections has shown the advisability of long-term outpatient treatment with antibacterial drugs.

Membrane markers, karyotypic abnormalities, ultrastructure and functional properties of lymphocytes in a case of ‘D-cell’ chronic lymphatic leukemia

1984 ◽  
Vol 8 (2) ◽  
pp. 223-237
Author(s):  
Jean-Pierre Bergerat ◽  
Jean-Marie Lang ◽  
Salomon Levy ◽  
Marie-Marthe Tongio ◽  
Francoise Uettwiller ◽  
...  
Keyword(s):  
Functional Properties ◽  
Chronic Lymphatic Leukemia ◽  
Membrane Markers ◽  
Lymphatic Leukemia ◽  
D Cell

scholarly journals Blood kinetics, tissue distribution, and radioimaging of anti-common chronic lymphatic leukemia antigen (cCLLa) monoclonal antibody CLL2 in mice transplanted with cCLLa-bearing human leukemia cells

Blood ◽  
1990 ◽  
Vol 75 (9) ◽  
pp. 1853-1861 ◽  
Author(s):  
GB Faguet ◽  
JF Agee ◽  
JT DiPiro
Keyword(s):  
Monoclonal Antibody ◽  
Specific Activity ◽  
Human Leukemia ◽  
Chronic Lymphatic Leukemia ◽  
Prolymphocytic Leukemia ◽  
Normal Tissues ◽  
Lymphatic Leukemia ◽  
Human Leukemia Cells ◽  
Glycoprotein Antigen ◽  
Leukemia Antigen

Abstract The blood kinetics and biodistribution of anti-common chronic lymphatic leukemia antigen (cCLLa) monoclonal antibody (MoAb) CLL2 were assessed in mice bearing cCLLa+ tumors. The cCLLa is a 69-Kd glycoprotein antigen expressed selectively by malignant B cells in human CLL, hairy cell leukemia (HCL), and prolymphocytic leukemia. Immunoreactive 125I- CLL2 (5 micrograms/mouse, specific activity 4.3 microCi/micrograms) was injected intravenously in mice bearing HCL-derived EH xenografts, and blood kinetics and biodistribution were ascertained up to 16 days postinjection. Radioimages were also obtained up to 72 hours after injecting 10 micrograms/mouse (specific activity 50.1 microCi/micrograms) of 125I-CLL2. Distinct 125I-CLL2 blood kinetics were observed in EH engrafted compared with tumor-free mice including: a longer 125I-CLL2 T 1/2 (153 hours v 72 hours), and a considerably greater blood clearance (173 mg/h v 54.7 mg/h) with biexponential rather than monoexponential configuration; and a greater volume of antibody distribution (31,483 mg v 5,729 mg). These data suggest more rapid tissue uptake by grafted tumours. Preferential 125I-CLL2 uptake by EH tumours relative to normal tissues was observed beginning 24 hours postinjection (mean ratio, 4.2) with average peak tumor 125I-CLL2 levels of 428.7 pg/mg. 125I-CLL2 uptake selectivity by EH tumor cells was also supported by: (1) negligible 125I-CLL2 uptake by cCLLa- Molt-4 xenografts (average 29.1 pg/mg 24 hours postinjection); (2) background uptake of cCLLa-irrelevant MoAb 131I-LEU1 by CD5- EH xenografts (average 31.4 pg/mg 48 hours postinjection); and (3) by scintigraphy. The EH xenograft mouse model might be useful to ascertain preclinically the anti-tumor effect of anti-cCLLa MoAbs and of their conjugated derivatives.

scholarly journals Osmotic fragility of peripheral blood lymphocytes in chronic lymphatic leukemia and malignant lymphoma

Blood ◽  
1978 ◽  
Vol 51 (4) ◽  
pp. 645-651 ◽  
Author(s):  
P Resnitzky ◽  
N Reichman
Keyword(s):  
Malignant Lymphoma ◽  
Peripheral Blood ◽  
Osmotic Fragility ◽  
Peripheral Blood Lymphocytes ◽  
Chronic Lymphatic Leukemia ◽  
Control Groups ◽  
Blood Lymphocytes ◽  
Lymphatic Leukemia ◽  
Additional Diagnostic Parameter ◽  
The Difference

Abstract The osmotic fragility (OF) of peripheral blood lymphocytes from patients with chronic lymphatic leukemia (CLL) and non-Hodgkin malignant lymphoma (ML) was investigated employing an automatic recording method and compared with that of lymphocytes from healthy subjects and from patients suffering from various non-neoplastic diseases. The curves from CLL and ML showed a pattern of increased lymphocyte OF compared with those of the two control groups, and the difference was statistically significant ( less than 0.001). In CLL the increase in OF was more pronounced than in ML, and the shape of the curve was different from that in the other groups. The employment of peripheral blood lymphocyte OF as an additional diagnostic parameter in the diagnosis of CLL and ML is suggested.

Sign in / Sign up

Export Citation Format

Share Document